Table 2 Comparison of first-line treatments for uterine versus non-uterine LMS
Treatment | Uterine LMS | Non-uterine LMS | Total LMS |
|---|---|---|---|
(n = 24), | (n = 24), | (N = 48), | |
n (%) | n (%) | n (%) | |
Anthracycline-based | 7 (29.2) | 11 (45.8) | 18 (37.5) |
Gemcitabine-based | 11 (45.8) | 10 (41.7) | 21 (43.8) |
Alkylating agents | 1 (4.2) | 1 (4.2) | 2 (4.2) |
Angiogenesis inhibitors | 1 (4.2) | 1 (4.2) | 2 (4.2) |
Trabectedin | 2 (8.3) | 1 (4.2) | 3 (6.3) |
Other | 2 (8.3) | 0 (0.0) | 2 (4.2) |